Consenso de expertos sobre el uso de alemtuzumab en la práctica clínica diaria en España

Meca-Lallana, José; Fernández-Prada, María; Vázquez, Elisa García; Guillén, Santiago Moreno; Romero, S. Otero; Hidalgo, M. Rus; Guimerans, Luisa María Villar; Madueño, Sara Eichau; Fernández, Óscar; Ayuso, Guillermo Izquierdo; Cermeño, José Carlos Álvarez; García, Cecilio; González, Rafael Arroyo; Ruíz, Luís Brieva; Hernández, C. Calles; Merino, A. García; González-Platas, Montserrat; Pérez, Miguel Ángel Hernández; Torres, E. Moral; Urtaza, Javier Olascoaga; Oliva‐Nacarino, Pedro; Oreja‐Guevara, Celia; Castillo, R. Ortiz; Oterino, Agustı́n; González, José María Prieto; Ramió-Torrentà, Lluı́s; Rodríguez‐Antigüedad, Alfredo; Sáiz, Albert; Tintoré, Mar; Gairín, Xavier Montalbán

doi:10.1016/j.nrl.2019.11.003

Cited by 6 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…54 Indivíduos sob alemtuzumab devem manter estas recomendações nas duas semanas pré-tratamento e durante pelo menos um mês após a última administração. 53,[55][56][57] O SMX/TMP é eficaz na prevenção da listeriose, sendo utilizado como profilaxia em doentes sob alemtuzumab. 53…”

Section: Infeção Por Listeriaunclassified

Protocolo de Prevenção e Tratamento de Infeções Associadas à Terapêutica Imunossupressora de Doenças Autoimunes

et al. 2021

View full text Add to dashboard Cite

We propose a guideline about the risk, prevention and treatment of infection in the patient under immunomodulatory or immunosuppressive therapy in the context of autoimmune or autoinflammatory disease. It is divided into three sections: drugs and associated risk of infection; immunizations; risk, prevention, and treatment of specific infections. The treatment of autoimmune diseases involves the use of immunosuppressive or immunomodulatory therapies, with an increasing number of new drugs being used. It is associated with an increased risk of infection, which may be present globally or only for specific agents, varying widely depending on the pharmacological class and even within the same class. The prevention strategy and clinical management need to be individually tailored and there are several key factors: characterization of the disease that prompts the immunosuppression, understanding of the mechanism of action of the immunosuppressive drug, knowledge of previous infections, recognition of risk factors, laboratory test results, vaccine administration, monitoring of clinical signs and symptoms and patient education.

show abstract

Section: Infeção Por Listeriaunclassified